Tempest Therapeutics (TPST) - Projected Sales Volume
Tempest Therapeutics (TPST) develops targeted small-molecule drugs to modulate tumor immunity. The company's sales history and forecasts are based on the work of US laboratories and partnerships with clinics. The 0.00 level captures the current state of the metric. The business is currently preparing final tests for a liver cancer drug, seeking to attract external investors for joint financing.
Summary analytical data breakdowns for Tempest Therapeutics Inc (TPST)
- current price and projected stock value:
- market capitalization indicators:
- book capitalization information:
- debt level and financial liquidity data:
Total Debt to Capital Tempest Therapeutics|TPST - Long-Term Liabilities to Capital|Short-Term Debt to Equity Tempest Tx|TPST - Company Total Debt Obligations|Debt to Book Value Tempest Therapeutics Inc|TPST - Amount of Long-Term Liabilities|Company Current Liabilities Tempest Therapeutics|Quick Liquidity Indicator tempesttx.com
- company profitability and valuation multiples indicators:
TPST - Profit After Payment of Taxes|Projected Future Earnings Tempest Therapeutics|TPST - Company Value to Net Income|Forward P/E Multiple Tempest Therapeutics, Inc.|TPST - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Therapeutics Inc|TPST - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Tempest Therapeutics|TPST - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months tempesttx.com|TPST - Earnings per share trend in current year|Earnings growth forecast for next year Tempest Therapeutics
- total revenue and sales volume data:
Basic company analysis:Tempest Therapeutics TPST
Institutional capital evaluates Tempest Therapeutics (TPST) through the lens of the potential monetization of its oncology pipeline. This indicator compares market capitalization with expected revenue to identify the degree of asset overvaluation. By analyzing the organization's projected sales, the investor sees a correlation between price and fundamental expectations. For a biotech company with transparent management and clear regulatory milestones, such a metric confirms the validity of the valuation, making the asset more predictable.
Key competitors
Company Future Sales Volume ONC (BeiGene Ltd)|Company Projected Revenue Volume HALO|Projected Sales Volume RVMD (Revolution Medicines, Inc.)|Ascentage Pharma Group International (AAPG) - Company Expected Sales Volume|CGON - Company Projected Revenue|UroGen Pharma Corp (URGN) - Company Future Sales Volume|Bicara Therapeutics Inc. (BCAX) - Company Projected Revenue|Company Expected Revenue PSNL (personalis.com)|ERAS (Erasca) - Projected Sales Volume|Company Expected Sales Volume Delcath Systems Inc DCTH|Company Projected Revenue YmAbs (YMAB)|Company Future Sales Aura Corp|Candel Therapeutics, Inc. - Company Future Sales Volume|Company Projected Revenue Volume ARAY (accuray.com)|SLS: Company Future Sales Volume|Company Future Revenue ACTU (Actuate Therapeutics Inc.)|CTOR (Citius Oncology, Inc) - Company Future Sales Volume|HURA: Company Projected Revenue Volume|TARA (Protara Therapeutics) - Projected Sales Volume|FATE: Company Future Revenue|Projected Sales Volume WHWK|TCRX - Company Expected Sales Volume|Company Projected Revenue Champions Oncology, Inc. CSBR|Company Future Revenue XBIT|CEL-SCI Corp - Projected Sales Volume|OSTX - Projected Sales Volume|Radiopharm Theranostics (RADX) - Company Projected Revenue|Company Expected Revenue ARTV (Artiva Biotherapeutics)|ANL (Adlai Nortye Ltd) - Projected Sales Volume|Company Expected Sales Volume Veru Corporation VERU|Company Future Sales Volume XLO (Xilio Therapeutics, Inc.)|Projected Sales Volume renovarobio.com (RENB)|Mural Oncology - Company Future Sales Volume|Company Projected Revenue Volume KAPA (Kairos Pharma Limited)|OnKure - Projected Sales Volume|Company Future Sales CytoMed Therapeutics GDTC|CRIS: Projected Sales Volume|Company Future Sales Volume Apollomics|Company Projected Revenue Tharimmune|Advanced Biomed Corp (ADVB) - Company Future Sales|Company Future Sales Volume GNPX (Genprex, Inc)|Company Projected Revenue Volume CLDI|Company Projected Revenue Sunshine Biopharma SBFM|XBIO (Xenetic Biosciences Inc.) - Company Expected Revenue|SLRX - Company Projected Revenue|Company Future Sales Purple Biotech Ltd PPBT|AONC (aoncology.com) - Company Future Sales Volume|BGNE: Company Projected Revenue Volume|CKPT (Checkpoint Therapeutics) - Projected Sales Volume|Company Future Sales Volume Elevation Oncology Inc. (ELEV)|Projected Sales Volume ICAD|Projected Sales Volume ikenaoncology.com (IKNA)|Company Projected Revenue Notable Labs Inc. NTBL|VIRX: Company Revenue Forecast|MorphoSys AG - Projected Sales Volume|nayabiosciences.com (NAYA) - Company Future Sales Volume|AAPGV: Projected Sales Volume
